Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : TAK crawled time : 23:00 save search
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.38 0.15% -0.67% 2.9K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
entyvio fda disease active for therapy
Checkpoint Inhibitors Market Forecast Reveals Impressive Growth With Focus on Novel Therapies and Regional Expansion
Published: 2024-02-12 (Crawled : 23:00) - prnewswire.com
GLAXF | News | $19.54 -3.77% 0
|
Health Technology
|
| O: 3.52%
H: 0.0%
C: -1.18%
AZNCF | News | $140.3 1.13% 0
|
Health Technology
|
| O: 0.06%
H: 2.34%
C: 2.29%
ALPMY | News | $9.49 -0.42% 55K
|
Manufacturing
|
| O: 0.37%
H: 0.74%
C: 0.28%
TAK | News | $13.38 0.15% -0.67% 2.9K
|
Health Technology
|
| O: 0.14%
H: 0.35%
C: 0.07%
NVS | News | $97.28 2.27% 1.47% 190K
|
Health Technology
|
| O: -0.34%
H: 0.23%
C: -1.13%
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: 0.7%
H: 0.0%
C: 0.0%
GSK | News | $41.24 1.6% 0.0% 1.6K
|
Health Technology
|
| O: 1.22%
H: 0.07%
C: -0.43%
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: -0.96%
H: 1.75%
C: 1.75%
BMY | $48.72 -0.55% 250K
|
Health Technology
|
| O: -0.18%
H: 0.48%
C: -1.91%
ABBV | News | $168.48 -0.63% 110K
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
ZLAB | $16.07 6.28% 28K
|
Health Technology
|
| O: -1.15%
H: 1.03%
C: -1.5%
VRTX | $404.91 1.25% 1.43% 1.8K
|
Health Technology
|
| O: -0.28%
H: 0.49%
C: -0.32%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
IPHA | $2.37 -2.27% -7.02% 2
|
Health Technology
|
| O: -3.1%
H: 1.2%
C: -0.8%
INCY | $51.65 -0.52% -0.58% 11
|
Health Technology
|
| O: 3.8%
H: 1.1%
C: -1.17%
BIIB | $200.31 3.69% 470K
|
Health Technology
|
| O: -3.72%
H: 0.58%
C: -3.82%
AZN | News | $71.19 0.48% 1M
|
Health Technology
|
| O: -0.26%
H: 0.73%
C: -0.36%
ARGX | $378.54 0.92% 28K
|
Health Technology
|
| O: -2.3%
H: 1.65%
C: 0.83%
AMGN | News | $270.69 -1.04% 120K
|
Health Technology
|
| O: 0.06%
H: 0.31%
C: -1.4%
expansion growth market
Global Antibodies Market Set to Soar, Projected to Reach $524.8 Billion by 2030 with a CAGR of 12.9%
Published: 2023-09-12 (Crawled : 23:00) - prnewswire.com
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
|
| O: -1.8%
H: 0.0%
C: 0.0%
TAK | News | $13.38 0.15% -0.67% 2.9K
|
Health Technology
|
| O: 0.63%
H: 0.5%
C: 0.31%
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: 1.05%
H: 0.73%
C: 0.14%
BMY | $48.72 -0.55% 250K
|
Health Technology
|
| O: 0.02%
H: 0.55%
C: -1.0%
ABBV | News | $168.48 -0.63% 110K
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: 0.0%
RARE F | $45.11 3.25% 3.04% 0
|
Health Technology
|
| O: -0.02%
H: 1.4%
C: -1.07%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
MOR | News | $18.04 0.45% 0.44% 0
|
Health Technology
|
| O: 0.0%
H: 0.63%
C: -1.98%
IOVA M | $11.86 4.77% 4.55% 1.8K
|
Health Technology
|
| O: -0.34%
H: 0.51%
C: -8.5%
INCY | $51.65 -0.52% -0.58% 11
|
Health Technology
|
| O: 0.0%
H: 0.53%
C: -1.76%
BIIB | $200.31 3.69% 470K
|
Health Technology
|
| O: 0.07%
H: 0.53%
C: -1.05%
AMGN | News | $270.69 -1.04% 120K
|
Health Technology
|
| O: -0.37%
H: 0.34%
C: -0.81%
reach global set market
Global CNS Therapeutics Strategic Business Report 2023: Burgeoning Global Aging Populace, Longer Life Expectancy to Drive CNS Demand
Published: 2023-06-30 (Crawled : 23:00) - prnewswire.com
ALKS | $24.26 0.79% 0.78% 25
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
| Email alert
Add to watchlist
NBIX | News M | $140.09 4.81% 4.6% 340
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
| Email alert
Add to watchlist
UCBJY | $65.26 0.51% -4.38% 0
|
Manufacturing
| Email alert
Add to watchlist
UCBJF | $128.725 2.12% 0
|
Health Technology
| Email alert
Add to watchlist
AZNCF | News | $140.3 1.13% 0
|
Health Technology
| Email alert
Add to watchlist
PFE | News 4 | $26.32 0.23% 0.15% 88K
|
Health Technology
| Email alert
Add to watchlist
TAK | News | $13.38 0.15% -0.67% 2.9K
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $96.0 0.94% 0
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $97.28 2.27% 1.47% 190K
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.72 -0.55% 250K
|
Health Technology
| Email alert
Add to watchlist
AZN | News | $71.19 0.48% 1M
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $168.48 -0.63% 110K
|
Health Technology
| Email alert
Add to watchlist
report business life global therapeutics
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
Published: 2023-05-25 (Crawled : 23:00) - globenewswire.com
TAK | News | $13.38 0.15% -0.67% 2.9K
|
Health Technology
|
| O: -0.62%
H: 0.62%
C: -0.12%
HCM | $18.25 7.73% 6.92% 0
|
Health Technology
|
| O: 7.45%
H: 3.66%
C: 2.06%
drug review treatment application
Stem Cell Therapy Global Market Report 2022: Advancements in Stem Cell Clinical Trials Fuels Growth
Published: 2023-04-05 (Crawled : 23:00) - prnewswire.com
TAK | News | $13.38 0.15% -0.67% 2.9K
|
Health Technology
|
| O: 1.24%
H: 2.42%
C: 1.94%
report cell trials global therapy growth market
Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma
Published: 2023-02-13 (Crawled : 23:00) - biospace.com/
TAK | News | $13.38 0.15% -0.67% 2.9K
|
Health Technology
|
| O: -1.37%
H: 0.69%
C: 0.51%
cabometyx renal benefits cell carcinoma nivolumab
Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Published: 2023-02-07 (Crawled : 23:00) - biospace.com/
TAK | News | $13.38 0.15% -0.67% 2.9K
|
Health Technology
|
| O: -0.13%
H: 1.01%
C: 0.89%
CTLT | $56.05 0.04% 46K
|
Health Technology
|
| O: 3.66%
H: 4.45%
C: 3.07%
EXEL | $23.38 0.39% 43K
|
Health Technology
|
| O: -0.64%
H: 1.11%
C: 0.76%
year financial update results
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy
Published: 2022-12-08 (Crawled : 23:00) - biospace.com/
TAK | News | $13.38 0.15% -0.67% 2.9K
|
Health Technology
|
| O: -0.07%
H: 1.09%
C: 1.09%
ntact-01 lung immunotherapy trial update cancer
Puma Biotechnology Reports Third Quarter 2022 Financial Results
Published: 2022-11-03 (Crawled : 23:00) - biospace.com/
TAK | News | $13.38 0.15% -0.67% 2.9K
|
Health Technology
|
| O: -0.91%
H: 0.92%
C: 0.77%
PBYI | $5.13 -0.77% -0.98% 32
|
Health Technology
|
| O: 0.0%
H: 1.85%
C: -0.93%
financial results
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
Published: 2022-05-26 (Crawled : 23:00) - biospace.com/
TAK | News | $13.38 0.15% -0.67% 2.9K
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.64%
H: 1.53%
C: 0.82%
adcetris
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
Published: 2022-02-14 (Crawled : 23:00) - biospace.com/
TAK | News | $13.38 0.15% -0.67% 2.9K
|
Health Technology
|
| O: 0.27%
H: 0.2%
C: 0.0%
BMY | $48.72 -0.55% 250K
|
Health Technology
|
| O: -0.01%
H: 0.22%
C: -0.09%
EXEL | $23.38 0.39% 43K
|
Health Technology
|
| O: -0.27%
H: 1.12%
C: -0.59%
opdivo renal trial cel cell carcinoma nivolumab
Novavax Reports Third Quarter 2021 Financial Results and Operational Highlights
Published: 2021-11-04 (Crawled : 23:00) - biospace.com/
TAK | News | $13.38 0.15% -0.67% 2.9K
|
Health Technology
|
| O: 0.35%
H: 0.91%
C: 0.77%
NVAX | $4.19 2.95% 3.21% 12K
|
Health Technology
|
| O: -5.97%
H: 2.42%
C: -2.26%
financial results results
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
Published: 2021-09-22 (Crawled : 23:00) - biospace.com/
TAK | News | $13.38 0.15% -0.67% 2.9K
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: -1.11%
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: 0.5%
H: 0.36%
C: -0.86%
ARCT 4 | $27.82 -0.39% 28K
|
Health Technology
|
| O: 1.81%
H: 2.1%
C: -0.32%
covid expansion collaboration vaccine ceo
FDA Approves Tissue-Based NGS Companion Diagnostic for Takeda's Targeted Therapy for NSCLC Patients with EGFR Exon20 Insertion Mutations
Published: 2021-09-15 (Crawled : 23:00) - prnewswire.com
TMO | News | $574.59 4.78% 1.29% 12K
|
Health Technology
|
| O: -0.15%
H: 0.12%
C: -0.3%
TAK | News | $13.38 0.15% -0.67% 2.9K
|
Health Technology
|
| O: 0.41%
H: 1.11%
C: 0.76%
fda therapy fda approval diagnostic
Insights on the Targeted Therapeutics Global Market to 2031 - Featuring Sanofi, Takeda Pharmaceutical and Novartis Among Others
Published: 2021-07-30 (Crawled : 23:00) - prnewswire.com
GSK | News | $41.24 1.6% 0.0% 1.6K
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $97.28 2.27% 1.47% 190K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
| Email alert
Add to watchlist
TAK | News | $13.38 0.15% -0.67% 2.9K
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.72 -0.55% 250K
|
Health Technology
| Email alert
Add to watchlist
Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021
Published: 2021-07-26 (Crawled : 23:00) - biospace.com/
TAK | News | $13.38 0.15% -0.67% 2.9K
|
Health Technology
|
| O: -0.42%
H: 0.36%
C: 0.3%
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: 0.56%
H: 0.19%
C: 0.03%
ARCT 4 | $27.82 -0.39% 28K
|
Health Technology
|
| O: -0.26%
H: 4.13%
C: 0.0%
financial results results
Gainers vs Losers
| 71% | 29% |
Top 10 Gainers
CZOO | $9.98 100.0% 330K
|
AMST | $3.48 74.0% 21M
|
Technology Services
BOF | $1.78 52.14% 15M
|
CSSE 4 | $0.2184 43.4% 36M
|
Consumer Services
ACB | $7.32 16.56% 780K
|
Process Industries
AEYE | $15.42 14.39% 150K
|
Technology Services
BACK | $3.75 13.64% 44K
|
Health Care and Social Assistan...
CGC | $8.835 12.55% 740K
|
Process Industries
BW | News | $1.0002 9.05% 190K
|
Electronic Technology
BILI | $12.525 9.01% 3.5M
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.